“Geraldine Harriman”的意思、由来-开放百科全书

Geraldine C. Bussolaria Harriman is a chemist and biotech entrepreneur with leadership roles in multiple scientific companies.

Education

Harriman received a B.S. degree in chemistry from American International College. She studied Biomedical and Pharmaceutical Sciences with Prof. Elie Abushanab at the University of Rhode Island, receiving her doctorate in 1991. Harriman completed postdoctoral studies with Prof. Gunda Georg^[1] at the University of Kansas, focusing on the medicinal chemistry of paclitaxel analogs.^[2]

Career

Harriman's first industrial position was at the immunology start-up LeukoSite,^[3] which was acquired by Millennium Pharmaceuticals in 1999.^[4] Over the next seven years, Harriman rose to become the Head of Chemistry at Millennium, when she was recruited by Galenea in 2007. She served as VP and Head of Chemistry there until 2010, when she was appointed VP at Nimbus Therapeutics, formed by Atlas Ventures in 2009. Nimbus specialized in computational and outsourced drug discovery. The program Harriman oversaw - "Nimbus Apollo" - focused on targeting the acetyl-coA carboxylase pathway to treat fatty liver diseases such as Non-Alcoholic Steatohepatitis (NASH). Gilead acquired Nimbus Apollo for $1.2 billion USD in 2016.^[5]

In 2017, Harriman co-founded Atlas-backed HotSpot Therapeutics, which will seek for allosteric inhibitors to potentially treat autoimmune and metabolic disorders. Harriman is a co-inventor on over twenty small-molecule use patents and 30 scientific publications.^[6]

Awards

References

1. ^{{Cite web|url=https://sites.google.com/a/umn.edu/georggroup/alumni|title=Alumni - Georg Research Group|website=sites.google.com|access-date=2018-10-24}}
2. ^{{Citation|last=Georg|first=Gunda I.|title=Medicinal Chemistry of Paclitaxel|date=1994-12-07|work=ACS Symposium Series|pages=217–232|publisher=American Chemical Society|language=EN|doi=10.1021/bk-1995-0583.ch016|isbn=978-0841230736|last2=Harriman|first2=Geraldine C. B.|last3=Vander Velde|first3=David G.|last4=Boge|first4=Thomas C.|last5=Cheruvallath|first5=Zacharia S.|last6=Datta|first6=Apurba|last7=Hepperle|first7=Michael|last8=Park|first8=Haeil|last9=Himes|first9=Richard H.}}
3. ^{{Cite news|url=http://www.hotspotthera.com/team/|title=Team - HotSpot Therapeutics|work=HotSpot Therapeutics|access-date=2018-10-24|language=en-US}}
4. ^{{Cite news|url=https://www.nytimes.com/1999/10/15/business/millennium-set-to-buy-leukosite.html|title=Millennium Set To Buy Leukosite|access-date=2018-10-24|language=en}}
5. ^{{Cite news|url=https://www.forbes.com/sites/brucebooth/2016/04/04/atlas-backed-nimbus-delivers-its-apollo-mission-a-1-2b-gilead-partnership/#28f2368b5c22|title=Atlas-Backed Nimbus Delivers Its Apollo Mission: A $1.2B Gilead Partnership|last=Booth|first=Bruce|work=Forbes|access-date=2018-10-24|language=en}}
6. ^{{Cite web|url=https://www.crunchbase.com/person/geraldine-harriman#section-overview|title=Crunchbase Profile: Geraldine Harriman|last=|first=|date=October 2018|website=CrunchBase|archive-url=|archive-date=|dead-url=|access-date=}}
7. ^{{Cite news|url=https://venturefizz.com/stories/boston/2017-nevy-awards-recap-winners-pictures|title=The 2017 NEVY Awards Recap: Winners & Pictures|date=2017-05-18|work=VentureFizz|access-date=2018-10-24|language=en}}
8. ^{{Cite journal|date=1993-11-01|title=An efficient semisynthesis of taxol from (3R,4S)-N-Benzoyl-3-[(t-butyldimethylsilyl)oxy]-4-phenyl-2-azetidinone and 7-(Triethylsilyl)baccatin III|url=https://www.sciencedirect.com/science/article/pii/S0960894X01809793|journal=Bioorganic & Medicinal Chemistry Letters|language=en|volume=3|issue=11|pages=2467–2470|doi=10.1016/S0960-894X(01)80979-3|issn=0960-894X|last1=Georg|first1=Gunda I.|last2=Cheruvallath|first2=Zacharia S.|last3=Harriman|first3=Geraldine C.B.|last4=Hepperle|first4=Michael|last5=Park|first5=Haeil}}